General Statement of Disclosure:

CONSULTING FEES/HONORARIA: Kowa(MODEST), Pfizer(MODEST), Novo Nordisk(SIGNIFICANT), Novartis Corporation(SIGNIFICANT), Daiichi Sankyo(SIGNIFICANT), SCRIBE(SIGNIFICANT), CRISPR(MODEST), VAXXINITY(MODEST), Abbott Laboratories(MODEST), Silence Therapeutics(SIGNIFICANT), New Amsterdam Pharma(SIGNIFICANT), Emendobio(MODEST), Nodthera(MODEST), Amgen(MODEST), Esperion(MODEST), Boehringer Ingelheim(MODEST), Astra Zeneca(MODEST), Eli Lilly and Company(SIGNIFICANT), Cleerley(MODEST), Menarini(MODEST), MSD(MODEST) SPEAKER'S BUREAU: Novartis Corporation(SIGNIFICANT), Daiichi Sankyo(SIGNIFICANT) EQUITY INTERESTS/STOCK OPTIONS: PEMI31(MODEST), New Amsterdam Pharma(SIGNIFICANT), SCRIBE(SIGNIFICANT) RESEARCH/RESEARCH GRANTS: Regeneron(SIGNIFICANT), Amgen(SIGNIFICANT), Daiichi Sankyo(SIGNIFICANT), Sanofi(SIGNIFICANT), Ultragenix(SIGNIFICANT)

View Full Disclosure